Image: Streptacidiphilus sp.
April 18, 2014 — NovoBiotic Pharmaceuticals, LLC is awarded a NIH NIAID SBIR grant for “Selective Agents Against C. difficile Infection.”
“Combining our proprietary culturing platform with a species-targeted screen offers a great potential for discovering new therapeutics with unique modes of action and fewer side effects” - Dallas Hughes, President, NovoBiotic Pharmaceuticals, LLC.
January 15, 2013 — NovoBiotic Pharmaceuticals, LLC is awarded a National Science Foundation SBIR grant for “Novel Antibiotics from Marine Animal-Microbe Symbioses.”
“This is our first attempt as a company to use our platform technology in a marine setting. While the challenges are high, the opportunity for drug discovery in a marine setting is limitless.” Aram Salzman, CEO NovoBiotic Pharmaceuticals, LLC.
December 15, 2012 — NovoBiotic Pharmaceuticals, LLC is awarded $3 Million NIH NIAID Phase II Advanced Technology SBIR grant for “Drug Discovery from Slow Growing and Rare Microbial Species.”
“Once we move beyond traditional microbial culture techniques, we have only scratched the surface of the organisms that can be grown in the laboratory, and compounds which can be derived from them.” Aram Salzman, CEO NovoBiotic Pharmaceuticals, LLC.
May 1, 2010 — NovoBiotic Pharmaceuticals, LLC is awarded $3 Million NIH NIAID Phase II Advanced Technology SBIR grant for “Isolating Novel Fungi for Antibiotic Discovery.”
“This Phase II SBIR award is further validation that our in-situ microbial culture platform technology is relevant with a wide range of microorganisms.” Aram Salzman, CEO NovoBiotic Pharmaceuticals, LLC.
NovoBiotic is a drug discovery company harnessing "unculturable" microorganisms to develop new therapeutics.
For more information on NovoBiotic contact:
NovoBiotic Pharmaceuticals, LLC
767C Concord Avenue
Cambridge, MA 02138
ph: 1-617-864-2880 x105